Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Safety of Korean Medicine for Lumbar Stenosis Patients With Sciatica

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with radiating leg pain with or without low back pain (LBP) (walking pain NRS ≥4)~* Patients with dural sac cross-sectional area (DSCA) of \<100 mm2 or morphological grading ≥B as assessed on MRI~* Patients with clear neurogenic claudication symptoms (symptoms aggravated with walking, and alleviated upon resting in lumbar flexion position)~* Patients who have received surgery recommendation for lumbar spinal stenosis~* Patients with plans of receiving Korean medicine treatment for lumbar spinal stenosis for ≥2 months~* Patients who have agreed to study participation~Exclusion Criteria:~* Patients with vascular claudication~* Patients with other systemic diseases that may interfere with treatment effect or outcome interpretation~* Patients with soft tissue pathologies or pathologies of non-spinal origin that may cause LBP or radiating leg pain (e.g. spinal tumor, rheumatoid arthritis)~* Patients for whom acupuncture treatment may be inappropriate or unsafe (e.g. hemorrhagic diseases, blood clotting disorders, history of anti-coagulation medicine intake, serious diabetes with risk of infection, severe cardiovascular diseases, or other conditions deemed unsuitable for acupuncture treatment)~* Pregnant patients or patients planning pregnancy~* Patients with serious psychological disorders~* Patients unable to fill out study participation consent form~* Subjects deemed unsuitable for study participation as assessed by the researchers

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lumbar stenosis group (Type: None): Lumbar stenosis patients will be administered integrative Korean medicine treatment consisting of herbal medicine, Chuna manipulation, bee venom pharmacopuncture and pharmacopuncture, acupuncture, electroacupuncture, cupping, and other interventions, as needed.

Based on this trial design, predict the completion outcome and termination type (if applicable).